References
EAU Guidelines. Edn. presented at the EAU Annual Congress Barcelona 2019. EAU Guidelines Office; 2019.
Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, et al. Risk of metastatic disease on (68) gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU Int. 2019;124:401–7. https://doi.org/10.1111/bju.14828.
De Bruycker A, De Bleser E, Decaestecker K, Fonteyne V, Lumen N, De Visschere P, et al. Nodal Oligorecurrent prostate Cancer: anatomic pattern of possible treatment failure in relation to elective surgical and radiotherapy treatment templates. Eur Urol. 2019;75:826–33. https://doi.org/10.1016/j.eururo.2018.10.044.
Grootendorst MR, Cariati M, Pinder SE, Kothari A, Douek M, Kovacs T, et al. Intraoperative assessment of tumor resection margins in breast-conserving surgery using (18)F-FDG Cerenkov luminescence imaging: a first-in-human feasibility study. J Nucl Med. 2017;58:891–8. https://doi.org/10.2967/jnumed.116.181032.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent for publication was obtained from the patient included in this study.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Oncology - Genitourinary
Rights and permissions
About this article
Cite this article
Darr, C., Krafft, U., Fendler, W.P. et al. First-in-man intraoperative Cerenkov luminescence imaging for oligometastatic prostate cancer using 68Ga-PSMA-11. Eur J Nucl Med Mol Imaging 47, 3194–3195 (2020). https://doi.org/10.1007/s00259-020-04778-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-020-04778-y